Search Results - "Bourdon, D M"

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Nitric oxide: a key mediator in the early and late phase of carrageenan‐induced rat paw inflammation by Salvemini, Daniela, Wang, Zhi‐Qiang, Wyatt, Pamela S., Bourdon, David M., Marino, Margaret H., Manning, Pamela T., Currie, Mark G.

    Published in British journal of pharmacology (01-06-1996)
    “…1 The role of nitric oxide (NO) derived from constitutive and inducible nitric oxide synthase (cNOS and iNOS) and its relationship to oxygen‐derived free…”
    Get full text
    Journal Article
  2. 2

    Evidence of peroxynitrite involvement in the carrageenan-induced rat paw edema by SALVEMINI, D, WANG, Z.-Q, BOURDON, D. M, STERN, M. K, CURRIE, M. G, MANNING, P. T

    Published in European journal of pharmacology (15-05-1996)
    “…The role of peroxynitrite generated from nitric oxide and superoxide anion was investigated in a model of acute inflammation induced by the injection of…”
    Get full text
    Journal Article
  3. 3

    Identification of the adenylyl cyclase‐activating 5‐hydroxytryptamine receptor subtypes expressed in the rat submandibular gland by Bourdon, D M, Camden, J M, Landon, L A, Levy, F O, Turner, J T

    Published in British journal of pharmacology (01-05-2000)
    “…Serotonin (5‐hydroxytryptamine, 5‐HT) has been shown to increase cyclic AMP production in dispersed cell aggregates from the major salivary glands of the rat…”
    Get full text
    Journal Article
  4. 4

    (N)‐methanocarba‐2MeSADP (MRS2365) is a subtype‐specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets by BOURDON, D. M., MAHANTY, S. K., JACOBSON, K. A., BOYER, J. L., HARDEN, T. K.

    Published in Journal of thrombosis and haemostasis (01-04-2006)
    “…Adenosine diphosphate (ADP) initiates and maintains sustained aggregation of platelets through simultaneous activation of both the Gq‐coupled P2Y1 receptor and…”
    Get full text
    Journal Article
  5. 5
  6. 6
  7. 7

    Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy by Le Quintrec, Moglie, MD, PhD, Lionet, Arnaud, MD, Kandel, Christine, MD, Bourdon, Franck, MD, Gnemmi, Viviane, MD, Colombat, Magali, MD, PhD, Goujon, Jean-Michel, MD, Frémeaux-Bacchi, Véronique, MD, PhD, Fakhouri, Fadi, MD, PhD

    Published in American journal of kidney diseases (01-03-2015)
    “…C3 glomerulopathy (C3G) is a prototypic complement-mediated kidney disease. Rapidly progressive forms of C3G usually respond poorly to conventional treatments…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10